What to learn more about Clinical Studies? Click Here.
Current/Recent PH clinical research studies:
PHAR: Pulmonary Hypertension Association Registry
The main objective of PHAR is to measure and improve quality of life in patients with pulmonary arterial hypertension (PAH) or chronic thromboembolic pulmonary hypertension (CTEPH) by improving clinical care and developing best care practices.
U.S. CTEPH Registry:
The ultimate goal of the chronic thromboembolic pulmonary hypertension (CTEPH) registry is to improve CTEPH patients’ quality of life through better understanding of this disease and its best treatments.
OPUS: U.S. based Observational Drug Registry of Opsumit®(Macitentan) New Users in Clinical Practice
The purpose of the OPUS registry is to better understand the use of Opsumit® in clinical practice and to characterize the clinical course of patients who are initiating treatment. NCT02126943
SPHERE: Uptravi® (Selexipag): The users drug registry
The goal of the SPHERE registry is to better understand the use of Uptravi® in patients, how it is prescribed, and the clinical course of patients who are treated with this medication.
INCREASE: A Multi-Center, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of inhaled Treprostinil in Subjects with Pulmonary Hypertension due to Parenchymal Lung Disease.
The objective of this study is to determine if inhaled Treprostinil vs placebo is safe and effective in treating Pulmonary Hypertension due to Parenchymal Lung Disease. NCT02630316
TRITON: The Efficacy and Safety of Initial Triple vs Dual Oral Combination Therapy in Patients with Newly Diagnosed Pulmonary Arterial Hypertension: A Multi-Center, Double-Blind, Placebo-Controlled, Phase 3B Study
The objective of this trial is to compare the effectiveness and safety of using 3 approved pulmonary hypertension (PAH) medications (Uptravi®, Opsumit®, and Adcirca) toether vs 2 approved PAH medications (Opsumit® and Adcirca) for newly diagnosed patients who have not started medicine. NCT 0255831
Quality of Life in Pulmonary Hypertension
The study aims to develop a new patient reported clinical trial outcome for patients with pulmonary hypertension.
CRAB-PH: Correlation Between Estimated Right Atrial Pressure and BNP in Pulmonary Hypertension
This study is to evaluate if using an ultrasound to check how your pulmonary hypertension is affecting your heart is just as accurate as drawing a blood sample (BNP) during clinic visits. NCT02873039
GRASP (Genome Research in African-American Scleroderma Patients)
The objective of this study is to assess the severity of scleroderma in association with genetics in people of African descent to ultimately develop targeted treatment
Development of the Mawdsley Calcinosis Index in Systemic Sclerosis
This study aims to develop the first Patient Reported Outcome Measure of calcinosis, which is a disabling complication of scleroderma.
Raynaud’s Assessment Scale Development
This study aims to develop a novel patient reported clinical trial instrument for Raynaud’s phenomenon.
Scleroderma Diet Randomised Controlled Trial
A randomized controlled trial investigating the impact of food choices on scleroderma symptoms.
SENSCIS (Safety and Efficacy of Ninedanib in systemic sclerosis)
This trial is assessing the effectiveness of nintedanib for scleroderma patients with lung fibrosis. NCT 02597933
EUSTAR - DeSSipher –
This is a global registry of scleroderma patients
ReAS (Registry for advanced sarcoidosis)
ReSaPH (Registry of sarcoidosis-associated pulmonary hypertension)
This multi-center registry study of sarcoidosis associated pulmonary hypertension (SAPH) will characterize the demographics, clinical course, hemodynamics, pulmonary physiology, and disease management of SAPH. NCT 01467791
For more information about the research studies at our center, above at www.clinicaltrials.gov and search the NCT number provided.
COMPLETED TRIALS WITHIN LAST 2 YEARS:
Endothelial microparticles as a biomarker of pulmonary hypertension in systemic sclerosis
AMBITION: A randomized, double blind, placebo-controlled, multi-center study of first line
Ambrisentan and Tadalafil combination therapy in subjects with pulmonary arterial hypertension
MOTION: A Phase IV, Prospective, Single-Arm, Open-Label to Measure Outcomes in Patients with Pulmonary Arterial Hypertension not on active treatment
PHAROS (Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma)
This national registry study enrolled scleroderma patients with pulmonary hypertension and those at risk for pulmonary hypertension to characterize the progression and outcome of disease. NCT 003377949